In a Q&A with Jeff Casberg, MS, RPh, senior vice president of clinical pharmacy services at IPD Analytics, Casberg explains the evolution of specialty drugs, the future of GLP-1 competition and what to expect from the traditional drug pipeline.

This article details the potential regulatory approval pathways.

This article explains potential data and market exclusivity granted during the U.S. regulatory approval process.

This article details the FDA evaluation process and expedited review designations.

Competitors in the field of adalimumab and insulin products may soon include authorized biologics.

IPD Analytics experts discussed the impact of Covid-19 on the drug pipeline.